Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay

Antiviral Research

Volumn 94, Issue 1, 2012, Pages 54-56

  Li, Wei ^a   Zeng, Yanli ^a   Wang, Junjie ^a   Zhou, Bin ^a   Zhang, Jian ^a   Zhang, Hao ^a   Li, Jingtao ^a   Wu, Yingsong ^a   Hamoudi, Rifat ^b   Zhou, Yuanping ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hepatitis C Virus; IL28B; Single nucleotide polymorphism; Treatment response

Indexed keywords

INTERLEUKIN 28B;

ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; ELECTROPHORESIS; GENE AMPLIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TEMPERATURE; VIRUS DETECTION; VIRUS EXAMINATION; VIRUS GENE;

ADULT; ANIMALS; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; CHINA; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; TETRA;

EID: 84862817055     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2012.02.007     Document Type: Article

References (16)

1. Balagopal A., Thomas D.L., Thio C.L. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010, 139:1865-1876.
2. Galmozzi E., Del M.B., Rametta R., Dongiovanni P., Fracanzani A.L., Benedan L., Borroni V., Maggioni P., Fargion S., Valenti L. A tetra-primer amplification refractory mutation system polymerase chain reaction for the evaluation of rs12979860 IL28B genotype. J. Viral Hepatitis 2011, 18:628-630.
3. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
4. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
5. Hoofnagle J.H., Seeff L.B. Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 2006, 355:2444-2451.
6. Ito K., Higami K., Masaki N., Sugiyama M., Mukaide M., Saito H., Aoki Y., Sato Y., Imamura M., Murata K., Nomura H., Hige S., Adachi H., Hino K., Yatsuhashi H., Orito E., Kani S., Tanaka Y., Mizokami M. The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B. J. Clin. Microbiol. 2011, 49:1853-1860.
7. Nakamoto S., Kanda T., Imazeki F., Wu S., Arai M., Fujiwara K., Yokosuka O. Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand. J. Gastroenterol. 2011, 46:955-961.
8. Okayama N., Fujimura K., Nakamura J., Suehiro Y., Hamanaka Y., Hinoda Y. Evaluation of a new efficient procedure for single-nucleotide polymorphism genotyping: tetra-primer amplification refractory mutation system-polymerase chain reaction. Clin. Chem. Lab. Med. 2004, 42:13-16.
9. Rauch A., Kutalik Z., Descombes P., Cai T., Di Iulio J., Mueller T., Bochud M., Battegay M., Bernasconi E., Borovicka J., Colombo S., Cerny A., Dufour J.F., Furrer H., Gunthard H.F., Heim M., Hirschel B., Malinverni R., Moradpour D., Mullhaupt B., Witteck A., Beckmann J.S., Berg T., Bergmann S., Negro F., Telenti A., Bochud P.Y. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1345. e1-e7.
10. S, L., 2001. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. Chapter 9: Unit 9.8.
11. Sinn D.H., Kim Y.J., Lee S.T., Gwak G.Y., Choi M.S., Lee J.H., Koh K.C., Yoo B.C., Paik S.W. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J. Gastroenterol. Hepatol. 2011, 26:1374-1379.
12. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
13. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
14. Thompson A.J., Muir A.J., Sulkowski M.S., Ge D., Fellay J., Shianna K.V., Urban T., Afdhal N.H., Jacobson I.M., Esteban R., Poordad F., Lawitz E.J., McCone J., Shiffman M.L., Galler G.W., Lee W.M., Reindollar R., King J.W., Kwo P.Y., Ghalib R.H., Freilich B., Nyberg L.M., Zeuzem S., Poynard T., Vock D.M., Pieper K.S., Patel K., Tillmann H.L., Noviello S., Koury K., Pedicone L.D., Brass C.A., Albrecht J.K., Goldstein D.B., McHutchison J.G. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010, 139(120-9):e18.
15. Ye S., Dhillon S., Ke X., Collins A.R., Day I.N. An efficient procedure for genotyping single nucleotide polymorphisms. Nucleic Acids Res. 2001, 29:1-8.
16. Yu M.L., Chuang W.L. Treatment of chronic hepatitis C in Asia: when East meets West. J. Gastroenterol. Hepatol. 2009, 24:336-345.